ml-3000 has been researched along with rofecoxib in 3 studies
| Studies (ml-3000) | Trials (ml-3000) | Recent Studies (post-2010) (ml-3000) | Studies (rofecoxib) | Trials (rofecoxib) | Recent Studies (post-2010) (rofecoxib) |
|---|---|---|---|---|---|
| 130 | 9 | 56 | 1,914 | 307 | 163 |
| Protein | Taxonomy | ml-3000 (IC50) | rofecoxib (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | 0.43 | |
| Cytochrome c oxidase subunit 2 | Homo sapiens (human) | 1.51 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.5 | |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 0.5 | |
| Calpain-2 catalytic subunit | Homo sapiens (human) | 0.02 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 1.8 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.3602 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.76 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.486 | |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.036 | |
| Sodium-dependent serotonin transporter | Macaca mulatta (Rhesus monkey) | 0.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daminet, S; Fernandes, J; Martel-Pelletier, J; Moreau, M; Pelletier, JP | 1 |
| Cerletti, C; Dell'Elba, G; Evangelista, V; Manarini, S; Rotondo, S | 1 |
| Kaur, G; Silakari, O | 1 |
1 review(s) available for ml-3000 and rofecoxib
| Article | Year |
|---|---|
Multiple target-centric strategy to tame inflammation.
Topics: Cyclooxygenase Inhibitors; Humans; Inflammation; Lactones; Lipoxygenase; Lipoxygenase Inhibitors; Molecular Structure; Prostaglandin-Endoperoxide Synthases; Pyrroles; Structure-Activity Relationship; Sulfones | 2017 |
1 trial(s) available for ml-3000 and rofecoxib
| Article | Year |
|---|---|
Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs.
Topics: Acetates; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Dogs; Double-Blind Method; Duodenoscopy; Duodenum; Gastroscopy; Lactones; Lipoxygenase Inhibitors; Pyrroles; Stomach; Sulfones; Treatment Outcome | 2005 |
1 other study(ies) available for ml-3000 and rofecoxib
| Article | Year |
|---|---|
The lipoxygenase-cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit.
Topics: Acetates; Animals; Aspirin; Blood Pressure; Cyclooxygenase Inhibitors; Disease Models, Animal; Electrocardiography; Heart Rate; Inflammation; Lactones; Leukotriene B4; Lipoxygenase Inhibitors; Male; Myocardial Ischemia; N-Formylmethionine Leucyl-Phenylalanine; Pyrroles; Rabbits; Sulfones; Thromboxane A2; Time Factors | 2006 |